Clinical Evaluation of the SEQureDx T21 Test In High Risk Pregnancies
NCT01555346 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3062
Last updated 2016-04-20
Summary
Whole blood samples will be collected from high-risk pregnant women to validate the clinical performance of the SEQureDx Trisomy 21 Test.
Conditions
- Down Syndrome
- Fetal Aneuploidy
Sponsors & Collaborators
-
Sequenom, Inc.
lead INDUSTRY
Principal Investigators
-
Juan-Sebastian Saldivar, MD · Sequenom Laboratories
Eligibility
- Min Age
- 18 Years
- Max Age
- 60 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-03-31
- Primary Completion
- 2014-10-31
- Completion
- 2015-12-31
Countries
- United States
- Canada
Study Locations
More Related Trials
-
Development of Non-invasive Prenatal Screening Test for Microdeletions Based on Fetal DNA Isolated From Maternal Blood
NCT01852708 ·Status: COMPLETED
-
Trisomy of Chromosome 21 Diagnosis by High Output Sequencing
NCT01118507 ·Status: COMPLETED
-
Automated Screen for Fetal Aneuploidy
NCT03635359 ·Status: UNKNOWN
-
Prenatal Screening for Down Syndrome With DNAFirst
NCT01966991 ·Status: COMPLETED
-
A New Prenatal Blood Test for Down Syndrome
NCT00877292 ·Status: COMPLETED
-
Clinical Performance of NIPT in Multiple Gestation Pregnancies
NCT04488393 ·Status: COMPLETED
-
Multiple Gestation Study
NCT02278536 ·Status: COMPLETED
-
Development of a Prenatal Test for Fetal Aneuploidy Detection
NCT01451671 ·Status: COMPLETED
-
Development of Non-invasive Prenatal Test for Microdeletion and Other Genetic Syndromes Based on Cell Free DNA
NCT02109770 ·Status: COMPLETED
-
High Risk Multiple Gestation Study
NCT02278874 ·Status: COMPLETED
-
Noninvasive Screening for Affected Pregnancies: Assay Development & Optimization in Affected Pregnancies
NCT01052688 ·Status: COMPLETED
-
Non-Invasive Screening for Fetal Aneuploidy
NCT00847990 ·Status: COMPLETED
-
Development of an Optimal Approach to Return of Results for Next-generation Sequencing for Prenatal Diagnosis
NCT02255825 ·Status: WITHDRAWN ·Phase: NA
-
Noninvasive Screening for Fetal Aneuploidy: A New Maternal Plasma Marker
NCT00971334 ·Status: COMPLETED
-
Non-Invasive Screening for Fetal Aneuploidy
NCT02317965 ·Status: UNKNOWN
-
Prenatal Genetic Diagnosis by Genomic Sequencing
NCT03936101 ·Status: COMPLETED
-
Non-Invasive Screening for Fetal Aneuploidy: A New Maternal Plasma Marker
NCT00770458 ·Status: COMPLETED
-
Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders
NCT06147414 ·Status: RECRUITING
-
PErsonalized Genomics for Prenatal Abnormalities Screening USing Maternal Blood
NCT03831256 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Comparison of Aneuploidy Risk Evaluations
NCT01663350 ·Status: COMPLETED
-
T21,18 and 13 Screening by Cell Free Fetal DNA in Low Risk Patients
NCT02424474 ·Status: COMPLETED ·Phase: NA
-
Investigation of the Impact of Noninvasive Prenatal Testing for Fetal Aneuploidy on Utilization of Prenatal Diagnostic Procedures and Pregnant Women's Views
NCT01708746 ·Status: COMPLETED
-
Clinical Follow-up of Pregnant Subjects Undergoing NIPT
NCT04595201 ·Status: RECRUITING
-
Development of a Fetal Sex Assay From Maternal Whole Blood
NCT00970047 ·Status: COMPLETED
-
Development of a Non-invasive Prenatal Test
NCT01451684 ·Status: COMPLETED